Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

This study is currently recruiting participants.

Verified June 2013 by Memorial Sloan-Kettering Cancer Center

Study NCT01582204 Information provided by Memorial Sloan-Kettering Cancer Center

First Received on April 18, 2012. Last Updated on June 17, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Renal Cancer

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

124IcG250

Additional drug interventions recognized in this trial

Sunitinib

More general drug interventions related to this trial

Sponsors listed in this trial